Diehl's Own^® CM

At a glance

• Common name: Cetyl myristoleate / CMO / CM
• Patent history: U.S. Patent 4,049,824 (1977) and U.S. Patent 5,569,676 (1996), both Dr. Harry W. Diehl
• Standardization: 20% powder (2394); approximately 40% oil (2390)
• Form: Powder / softgel-suitable oil
• Item Codes: 2394 (20% powder); 2390 (40% oil)

The Story Behind the Name

In the 1960s and 1970s, Dr. Harry W. Diehl was a research chemist at the National Institute of Arthritis, Metabolic, and Digestive Diseases at the NIH in Bethesda, Maryland. By that point in his career, Diehl had developed more than 500 novel compounds for the institute, including a method for synthesizing 2-deoxydextroribose used in Dr. Jonas Salk’s oral polio vaccine.

The work that led to cetyl myristoleate didn’t start with a research grant. It started with a neighbor — a carpenter — whose rheumatoid arthritis had progressed to the point of disability. Diehl began working at home, in his off-hours, looking for an answer.

Working through animal models, he made an unexpected observation: Swiss albino mice were entirely resistant to chemically induced arthritis. Ordinary lab mice developed the condition; Swiss albinos didn’t. Diehl traced the immunity to a specific compound in the Swiss albino strain — cetyl myristoleate — and characterized it, then patented it. U.S. Patent 4,049,824, issued September 20, 1977, covers cetyl myristoleate itself. U.S. Patent 5,569,676, issued October 29, 1996, covers a method for the treatment of osteoarthritis using the compound.

Diehl later developed osteoarthritis himself. He treated himself with his own preparation and reported recovery. His findings were published in the Journal of Pharmaceutical Sciences in March 1994.

Dr. Diehl passed away in 1999. Diehl’s Own® CM is the GCI Nutrients ingredient that carries the trademark license honoring his name on the product — the original compound, the original story.

What Diehl’s Own® CM Is

Cetyl myristoleate (CMO, CM) is a long-chain fatty-acid ester — specifically, the cetyl alcohol ester of myristoleic acid. It is supplied as a defined CMO blend in either powder or oil form, suited for capsules, softgels, and tablets in joint-comfort formulations.

Mechanism

The mechanism of cetyl myristoleate has been investigated in animal and in-vitro models since Diehl’s original work. Proposed mechanisms include surfactant and lubricant activity at the synovial joint surface, modulation of inflammatory mediator pathways (including the arachidonic acid cascade), and immune-system effects in arthritis-induced animal models. The compound has been characterized over decades of use as well-tolerated at the doses used in joint-comfort applications.

Why Formulators Choose Diehl’s Own® CM

• The original compound — supplied with the trademark honoring its discoverer.
• A real, documented backstory that brand owners can put on their package and on their site, differentiating from generic CMO.
• Documented use in canine and feline joint products as well as human applications (see the Pet Nutrition industry page).
• Compatible with the standard joint stack — glucosamine, chondroitin, MSM, hyaluronic acid, collagen.
• Sourced and qualified under GCI Sure™.

Where Diehl’s Own® CM Fits

Dosage formats: capsules, softgels, tablets, soft chews (pet), powders.

Industries served: dietary supplements; sports nutrition; pet nutrition (canine and feline joint formulations).

Technical Specifications

Reference values below are drawn from GCI’s product documentation. Request the current specification and lot-specific certificate of analysis before purchase. Detailed oil values apply only to item 2390; they are not powder specifications.

For cas number, test method, particle size, loss on drying, allergens, gmo status, request the current product documentation.

Ordering Information

Quality, Compliance & Certifications

Request current certificates and product statements for the selected grade; certification availability is subject to verification.

• Distributed under cGMP and the GCI Sure™ program.
• Request the current specification and lot-specific certificate of analysis.

Often Formulated With

• Glucosamine, chondroitin sulfate, MSM — the foundational joint stack.
• Hyaluronic acid, collagen peptides (Type II) — joint and connective tissue.
• Boswellia, curcumin — joint comfort with botanical positioning.
• SerraSure™ — joint comfort with systemic enzyme support.
• Omega-3 oils (DHA3Sure™) — broader joint and recovery formulations.

Resources

• Diehl’s Own® CM specification — request through the technical documents form
• Current COA — request via form
• The full backstory: Dr. Harry W. Diehl, NIH, and the discovery of cetyl myristoleate (linked from this page)

Bring Diehl’s Own® CM Into Your Next Formulation

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent disease. Diehl’s Own® is a registered trademark used under license by GCI Nutrients, Inc.